---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-157003"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:06:47.497966+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences announces redomiciliation to Delaware, shares to exchange 1:1

## Summary
- Parent company to change from Singapore to Delaware corporation via scheme of arrangement.
- All ordinary shares exchanged 1:1 for common stock of new Delaware parent, continues trading as WVE.
- Redomiciliation subject to shareholder and Singapore High Court approval; expected mid-2026.
- Preliminary proxy filed April 15, 2026; expected tax-free to U.S. shareholders.
- Cites administrative efficiencies and reduced compliance costs as benefits.

## SEC filing metadata
- accession: 0001193125-26-157003
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526157003/0001193125-26-157003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526157003/d116643d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-157003
- JSON: https://secwatch.observer/filing/0001193125-26-157003.json
- Plain text: https://secwatch.observer/filing/0001193125-26-157003.txt

## Source-grounded claims
- claim_id: c1b123ba460f7ed7d059728f6fe8e0f13e1304c3
  claim: Wave Life Sciences Ltd. entered into Implementation Agreement with Wave Life Sciences, Inc. (Wave-Delaware) valued at Exchange all Wave-Singapore ordinary shares for Wave-Delaware common stock on a one-for-one basis; R (effective 2026-04-15).
  evidence_excerpt: In order to complete the Redomiciliation, the boards of directors of each of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation (“ Wave-Delaware ”), approved the entry by Wave-Singapore and Wave-Delaware, respectively, into an Implementation Agreement (the “ Implementation Agreement ”). The Implementation Agreement was executed by Wave-Singapore and Wave-Delaware on April 15, 2026 and provides for a statutory procedure known as a scheme of arrangement (the “ Scheme of Arrangement ”) to be implemented by Wave-Singapore and Wave-Delaware under Singapore law, subject to approval of the shareholders of Wave-Singapore and the High Court of the Republic of Singapore.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312526157003/0001193125-26-157003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.